Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 26, 981–983 (1 September 2008) | doi:10.1038/nbt0908-981
Cost/success projections for US biodefense countermeasure development
&
Abstract
To the Editor: To protect civilians against biological weapons and bioterrorism, the US Department of Health and Human Services (HHS) has developed a list of essential medical countermeasure requirements. We performed a survey of candidate biodefense countermeasures in development and estimated their future clinical development costs, based on historical drug and vaccine development data.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
